A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma.

Saved in:
Bibliographic Details
Title: A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma.
Authors: Shouse G; Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA., Kaempf A; Biostatistics Shared Resource, Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Gordon MJ; Department of Lymphoma, MD Anderson Cancer Center, Houston, TX., Artz A; Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA., Yashar D; Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA., Sigmund AM; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH., Smilnak G; Division of Hematology/Oncology, Northwestern University, Chicago, IL., Bair SM; University of Colorado Cancer Center, University of Colorado, Aurora, CO., Mian A; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH., Fitzgerald LA; Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT., Bajwa A; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH., Jaglowski S; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH., Bailey N; Center for Blood Disorders and Cellular Therapy, Swedish Cancer Institute, Seattle, WA., Shadman M; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA., Patel K; Center for Blood Disorders and Cellular Therapy, Swedish Cancer Institute, Seattle, WA., Stephens DM; Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT., Kamdar M; University of Colorado Cancer Center, University of Colorado, Aurora, CO., Hill BT; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH., Gauthier J; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA., Karmali R; Division of Hematology/Oncology, Northwestern University, Chicago, IL., Nastoupil LJ; Department of Lymphoma, MD Anderson Cancer Center, Houston, TX., Kittai AS; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH., Danilov AV; Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.
Source: Blood advances [Blood Adv] 2023 Jul 25; Vol. 7 (14), pp. 3516-3529.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2473-9537
DOI:10.1182/bloodadvances.2022009309